Investigational drug · Phase 2
RBS2418
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Colorectal Cancer, Advanced Colorectal Cancer, Advanced Unresectable Hepatocellular Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "RBS2418"
First trial start
2025
Jan 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RBS2418", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Cancer
- Advanced Colorectal Cancer
- Advanced Unresectable Hepatocellular Carcinoma
Approved drugs for the same conditions: Colorectal cancer · Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RBS2418" as an intervention, largest first.
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaPivotal-lookingRecruiting
Riboscience, LLC.Industry
NCT07175441 · 220 participants (planned) · Start Apr 10, 2026 · Primary completion Apr 2027
Drug: RBS2418; STRIDE (durvalumab + tremelimumab) · For: Advanced Unresectable Hepatocellular Carcinoma
Sites: Baltimore, Maryland; Nashville, Tennessee; Dallas, Texas · 4 sites in all
Riboscience, LLC.Industry
NCT05270213 · 164 participants (planned) · Start Jul 11, 2022 · Primary completion Apr 2027
Drug: RBS2418; Pembrolizumab and 1 more · For: Advanced Cancer
Sites: Scottsdale, Arizona; Tucson, Arizona; Palo Alto, California · 14 sites in all
- Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal CancerPivotal-lookingRecruiting
Riboscience, LLC.Industry
NCT06824064 · 150 participants (planned) · Start Jan 17, 2025 · Primary completion Dec 2027
Drug: RBS2418; Placebo · For: Metastatic Colorectal Cancer; Advanced Colorectal Cancer
Sites: Newark, Delaware; Las Vegas, Nevada; Nashville, Tennessee · 8 sites in all
- Expanded Access RBS2418 TreatmentNo longer available
Riboscience, LLC.Industry
NCT05683470
Drug: RBS2418 · For: Expanded Access in Pancreatic Cancer
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Colorectal Cancer
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.